Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA
Xavier Castellsague, Paulo Naud, Song-Nan Chow, Cosette M Wheeler, Maria Julieta V Germar, Matti Lehtinen, Jorma Paavonen, Unnop Jaisamrarn, Suzanne M Garland, Jorge Salmeron, Dan Apter, Henry Kitchener, Julio C Teixeira, S Rachel Skinner, Genara Limson, Anne Szarewski, Barbara Romanowski, Fred Y Aoki, Tino F Schwarz, Willy AJ Poppe Show all
Journal of Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2014
BACKGROUND: We examined risk of newly detected human papillomavirus (HPV) infection and cervical abnormalities in relation to HPV type 16/18 antibody levels at enrollment in PATRICIA (Papilloma Trial Against Cancer in Young Adults; NCT00122681). METHODS: Using Poisson regression, we compared risk of newly detected infection and cervical abnormalities associated with HPV-16/18 between seronegative vs seropositive women (15-25 years) in the control arm (DNA negative at baseline for the corresponding HPV type [HPV-16: n = 8193; HPV-18: n = 8463]). RESULTS: High titers of naturally acquired HPV-16 antibodies and/or linear trend for increasing antibody levels were significantly associated with lo..View full abstract
Awarded by GlaxoSmithKline Biologicals SA
Awarded by NATIONAL CANCER INSTITUTE
This work was supported by GlaxoSmithKline Biologicals SA (NCT00122681). Cervarix is a registered trademark of the GlaxoSmithKline group of companies.